Fig. 6: Altered astrocyte response in rhFGF21-treated mice after stroke.

a Representative images of GFAP immunostaining in the perilesional brain tissue sections from tMCAO mice receiving PBS or rhFGF21, Scale bar=500 μm or 250 μm. b Relative GFAP-positive area in the cortical region surrounding the border of the lesion for 3 and 14 d post-injury. n = 6/group. ^*P < 0.05, ^***P < 0.001, by 2way-ANOVA with Sidak’s multiple comparison. c Gating strategy and quantification for GFAP⁺ astrocytes in the ipsilateral hemisphere 3 d after tMCAO. n = 6/group, ^****P < 0.0001 vs. sham group ^&P < 0.05 vs. MCAO group (1way-ANOVA with Tukey’s multiple comparison). d Quantitative RT-PCR for mRNA expression of Il-1β, Tnf-α, Il-6, Ccl3, Cxcl1, and Cxcl2 in sorted astrocytes. n = 8/group. ^*P < 0.05, ^**P < 0.01, by unpaired Student’s t-test. e, f The expression levels of BDNF and NGF in the cortex around the infarcted zone were detected by Western blot, and normalized to β-actin. n = 4/group. ^*P < 0.05, ^****P < 0.0001, determined by 1way-ANOVA with Tukey’s multiple comparison. g Double-immunofluorescence staining for GFAP/BDNF and GFAP/NGF in the perifocal cortex under PBS or rhFGF21 treatment condition at 3 d after tMCAO. Scale bar=100, 50, or 25 μm. n = 5/group. ^*P < 0.05, ^**P < 0.01, ^***P < 0.001, determined by unpaired Student’s t-test. Results are presented as mean ± SD.